Cargando…

The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?

The clinical benefit of immune checkpoint inhibitory therapy (ICT) in advanced melanomas is limited by primary and acquired resistance. The molecular determinants of the resistance have been extensively studied, but these discoveries have not yet been translated into therapeutic benefits. As such, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballotti, Robert, Cheli, Yann, Bertolotto, Corine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718690/
https://www.ncbi.nlm.nih.gov/pubmed/33276788
http://dx.doi.org/10.1186/s12943-020-01290-7